Alberto García-Hernández

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Philippe Gabríel Steg, Shamir R. Mehta, J. Wouter Jukema et al. · European Heart Journal · 2011 · 185 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN)

Philip Van Kerrebroeck, François Haab, J.C. Angulo et al. · European Urology · 2013 · 75 citations

Medicine, Pharmacotherapy, Urology +16

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial

Dick de Zeeuw, Ronny Renfurm, George L. Bakris et al. · The Lancet Diabetes & Endocrinology · 2018 · 48 citations · Full text

Medicine, Nephrology, Pharmacotherapy +13

Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

Quan Dong Nguyen, Yasir J. Sepah, Brian B. Berger et al. · International Journal of Retina and Vitreous · 2019 · 21 citations · Full text

Medicine, Ophthalmology, Pharmacology +16

Is Increasing Urinary Albumin a Better Marker for Microvascular than for Macrovascular Complication of Type 2 Diabetes mellitus?

Jose L. Herrera-Pombo, Manuel Aguilar‐Diosdado, Federico Hawkins et al. · Nephron Clinical Practice · 2005 · 14 citations

Medicine, Endocrinology, Internal Medicine +15